Discovering Ketamine with Dr. Edward Domino

Summary

This interview centers on the early history of ketamine and the career of Dr. Edward F. Domino, presented as a foundational figure in dissociative anesthetics, NMDA antagonism, and the broader study of arylcyclohexylamines. The speaker frames the conversation as historically important and ethically complex, emphasizing that Domino’s work should be understood in the context of mid-20th-century pharmaceutical research rather than judged solely by contemporary standards. The introduction highlights that Domino was the first person to administer ketamine to a human being and that his wife coined the term dissociative anesthetics, underscoring both his scientific and personal role in shaping the field. A major theme is the origin story of ketamine. Domino explains that his involvement began almost accidentally when his department chairman asked him, as a young instructor in pharmacology, to test compounds from a Detroit pharmaceutical company. He describes how ketamine emerged from a series of phencyclidine derivatives developed by chemists associated with Parke-Davis, Warner-Lambert, and Wayne State University, including Calvin Stevens and his students. Domino recounts the transition from animal studies to human testing, noting that he assembled a team with an anesthesiologist and began administering the compound to volunteers. One of the most memorable anecdotes involves early pain testing on a volunteer, including the famous testicle compression experiment, which demonstrated ketamine’s unusual anesthetic properties. The story is presented as both scientifically significant and emblematic of the era’s research culture. The interview also explores the psychiatric implications of ketamine. Domino discusses early research at the Lafayette Clinic, a Michigan state psychiatric hospital, where he worked with psychiatrist Elliot Luby. Together, they studied ketamine and related compounds in patients, including efforts to model schizophrenia and understand the psychological effects of dissociative drugs. Domino emphasizes that he learned the importance of collaboration and repeatedly credits colleagues for enabling the work. He also reflects on a personal clinical encounter with a depressed woman who reported that ketamine was the only drug that helped her depression. In retrospect, he regards this as an early missed opportunity to investigate ketamine’s antidepressant effects, and he explicitly states that he should have listened more carefully to the patient. This becomes one of the interview’s central lessons: patients may recognize therapeutic effects before the medical establishment does. Another significant topic is the ethics and historical context of pharmaceutical testing on prisoners. The speaker explains that ketamine’s first human use occurred in a prisoner population at Jackson Prison in Michigan, where pharmaceutical companies had a dedicated research facility. He acknowledges that such experiments are troubling by modern standards, but argues that they were not unusual for the time and that the prisoners consented and were compensated. The discussion raises questions about informed consent, coercive conditions, and how historical research should be interpreted today. The speaker’s goal is to prevent simplistic moral condemnation of Domino while still recognizing the ethical ambiguity of the research environment. The conversation then turns to later developments in ketamine science, especially its antidepressant potential and the search for mechanisms of action. Domino notes that ketamine’s mechanism remains complex and multi-phasic, and he advocates studying the individual enantiomers rather than the racemic mixture. He argues that r-ketamine, developed primarily in Japan, may offer antidepressant benefits with fewer dissociative side effects. He encourages further research into whether dissociation is necessary for antidepressant efficacy and suggests that the future of the field may lie in more selective analogs. He also mentions the importance of basic science in understanding depression and the need to investigate endogenous ligands and receptor mechanisms. A separate thread concerns sigma receptors, another area in which Domino contributed significantly. He credits Graham Chen at Parke-Davis with sparking his interest in sigma receptor research and presents this as another example of how industry collaborations shaped his career. Throughout the interview, Domino repeatedly returns to practical advice: get permission from supervisors, secure grant money, work with the right colleagues, and pursue honest science. He frames his own career as a mixture of chance, institutional support, and persistence, rather than genius alone. The interview also touches on the patent dispute involving Calvin Stevens, who patented ketamine-related compounds independently, creating conflict with Parke-Davis and Wayne State. Domino describes Stevens as an excellent chemist but criticizes the decision as dishonest and professionally damaging. This episode reinforces the interview’s broader moral theme: scientific progress depends not only on discovery but also on integrity and proper collaboration. Overall, the conversation is a detailed oral history of ketamine, spanning its discovery, first human administration, psychiatric research, ethical controversies, and future therapeutic possibilities. It presents Edward Domino as a pioneering but reflective scientist who values patient observation, collaboration, and honesty, while also acknowledging the complicated institutional and ethical landscape in which ketamine research emerged.